Navigation Links
Mylan Schedules Fourth Quarter Financial Results Conference Call and Live Webcast
Date:2/16/2009

PITTSBURGH, Feb. 16 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast on Thursday, February 19, 2009, at 5:00 p.m. ET to review the company's financial results for the fourth quarter, which ended December 31, 2008. Mylan will release its financial results on February 19 after the market closes.

The dial-in number to access the February 19 call is 888-287-5536 or 719-325-2126 for international callers. A replay, available for approximately seven days, will be available at 888-203-1112 or 719-457-0820 for international callers with access pass code 4584157.

To access a live webcast of the February 19 call, please log on to Mylan's Web site (www.mylan.com) at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on www.mylan.com for approximately seven days.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Receives FDA Approval for First-to-File Generic Depakote(R) ER
2. Mylan Declares Quarterly Preferred Stock Dividend
3. Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD
4. Mylan Receives Final FDA Approval for Generic Version of Prilosec(R) Delayed-Release Capsules, 40 mg
5. U.S. Patent and Trademark Office Issues Mylans Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
6. Mylan to Present at the 27th Annual J.P. Morgan Healthcare Conference
7. Mylans Matrix Receives Final FDA Approval for the Generic Version of the Antiretroviral Zerit(R) Capsules
8. Mylan Announces Move to NASDAQ Stock Market
9. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
10. Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
11. Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/24/2017)... ... ... Millions of families and businesses worldwide depend on high quality water from ... water. However, well water can also become contaminated with bacteria and odors from flood ... The EPA does not regulate private drinking water wells. Many states and towns do ...
(Date:9/24/2017)... ... ... boy was walking home and feeling down about himself. He didn’t think he was good ... he can do whatever he wants to do if he puts his mind to it. ... God created him with special talents and gifts. We see his internal dialogue change. He ...
(Date:9/24/2017)... ... ... The Other Sheep”: the ceremonial laws of Moses and the Holy Law of God reexamined. ... author, Maurice Caines. Maurice Caines resides in the sunny isle of Florida, but he ... Adventist Church for many years. He was previously a member of the Anglican Church ...
(Date:9/23/2017)... San Francisco, CA (PRWEB) , ... September 23, 2017 , ... ... Bay Area, is proud to announce a new blog post focused on the ARTAS® ... loss, they understandably hope to turn to the latest, most technologically sophisticated methods of ...
(Date:9/22/2017)... Albert Lea, MN (PRWEB) , ... September 22, 2017 , ... ... and video) at its rally to interview citizens on why they are rallying against ... stories and commitment to this effort against Dr. Noseworthy’s (CEO) decision to close the ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology: